Le Lézard
Classified in: Health
Subjects: CCA, FVT

ViewRay® to Present at the 2019 Piper Jaffray 31st Annual Healthcare Conference


CLEVELAND, Nov. 20, 2019 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the Company will participate in the 2019 Piper Jaffray 31st Annual Healthcare Conference in New York, New York. Scott Drake, President and CEO, will give a presentation at 1:30p.m. Eastern Time on Wednesday, December 4, 2019.

(PRNewsfoto/ViewRay, Inc.)

An audio webcast of the Company's presentation will be available on the investor relations section of ViewRay's website at www.viewray.com. A replay of the webcast will be available for 7 days after the date of the presentation.

About ViewRay
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

SOURCE ViewRay, Inc.


These press releases may also interest you

at 02:05
The Healthcare Information and Management Systems Society (HIMSS) and Elsevier, the global information analytics business specializing in science and health, are proud to announce the call for submissions for the Annual HIMSS-Elsevier Digital...

at 01:05
Regulatory News: Lysogene (Paris:LYS) (FR0013233475 ? LYS) today announced its corporate agenda* for 2020: 17 February 2020: Sales and cash position at the end of 2019 20 March 2020: 2019 annual results 22 April 2020: First...

at 01:05
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMvigor010 study evaluating Tecentriq® (atezolizumab) as an adjuvant (after surgery) monotherapy treatment did not meet its primary endpoint of...

at 01:05
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the decision to pause dosing patients in the global Phase III (PVO-1A-301) study designed to evaluate the efficacy and safety of palovarotene in patients with fibrodysplasia...

at 01:04
CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) recently announced that it has dosed the first patient in Australia in a clinical trial of CS1001, an investigational PD-L1 inhibitor developed by CStone, in combination with regorafenib,...

23 jan 2020
Sasakawa Health Foundation has announced the start of its first-ever social media campaign with organizations of persons affected by leprosy. Taking part are 17 people's organizations in 16 countries that are linking up...



News published on 20 november 2019 at 08:00 and distributed by: